Proactive Investors - Run By Investors For Investors

Tyme Technologies stock flies ahead of data release on SM-88 in fighting pancreatic cancer

The New York biotech will hold a conference call with analysts and investors on January 18 to discuss SM-88 preliminary Phase II pancreatic cancer data
A magnifying glass highlights the word cancer
The biotech's therapeutic approach takes advantage of a cancer cell’s metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress

Shares in Tyme Technologies Inc (NASDAQ:TYME) flew Tuesday after the New York-based clinical-stage biotechnology company said it will hold a conference call to discuss data from a Phase 2 clinical trial evaluating lead therapy SM-88 in battling pancreatic cancer.

The management team will hold a conference call with analysts and investors at 9 am EST on January 18 to discuss the SM-88 preliminary Phase 2 pancreatic cancer data.

This data will also be presented in four posters at the three-day Gastrointestinal Cancers symposium being organized by the American Society of Clinical Oncology, in San Francisco starting January 17.

Investors anticipating positive data sent shares of the biotech up 19.3% to $2.93.

READ: Lexaria Bioscience inks deal with Altria Ventures to develop reduced-risk nicotine products; shares soar

Tyme Technologies is developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress.

The biotech is developing SM-88, a novel combination therapy that utilizes a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down the cells’ key defenses and making them vulnerable to oxidative stress and death.

Tyme said its SM-88 therapy has demonstrated “efficacy in the treatment of multiple oncology indications, including breast and prostate, and pancreatic cancer” without serious adverse events.

The SM-88 program is expected to enter a pivotal trial in metastatic pancreatic cancer during 2019. 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full TYME profile View Profile

Tyme Technologies Inc Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use